FBIOP
Fortress Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.75
+1.02%Year over year
Reported trailing growth
- Revenue
- +15.5%
- EBITDA
- +321.1%
- EBIT
- +72.9%
- EPS
- +394.8%
- Free cash flow
- +257.1%
- Operating cash flow
- +257.2%
Forward estimates
Based on analyst estimates
- Revenue
- -35.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -5.8%
- EBITDA
- +80.7%
- EBIT
- +36.4%
- Net income
- +114.8%
- EPS
- +97.5%
- Free cash flow
- +30.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026